PUK18 - ECONOMIC EVALUATION OF THE USE OF SEVELAMER (RIFOSAR®) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL DISEASE, FROM THE PERSPECTIVE OF THE INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)
Abstract
Authors
D. Orozco J.L. Alcantara B. Flores F. Lemus A. Figueroa